Aligos Therapeutics (ALGS) Common Equity (2019 - 2026)

Aligos Therapeutics has reported Common Equity for 8 years, with the latest figure at $31.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 72.7% year-over-year to $31.8 million; the trailing twelve-month figure through Mar 2026 stood at $31.8 million (down 72.7% YoY), and the FY2025 full-year result was $53.5 million, up 284.81% from the prior year.
• Common Equity for Q1 2026 stood at $31.8 million, down from $53.5 million in the prior quarter.
• The five-year high for Common Equity was $152.9 million in Q1 2022, with the low at -$29.0 million in Q4 2024.
• Historically, Common Equity has averaged $78.9 million across 5 years, with a median of $71.8 million in 2025.
• Annual changes were most pronounced in 2024 — Common Equity tumbled 131.47% — and 2025, when it surged 284.81%.
• Aligos Therapeutics' Common Equity stood at $103.9 million in 2022, then fell by 11.38% to $92.1 million in 2023, then plunged by 131.47% to -$29.0 million in 2024, then surged by 284.81% to $53.5 million in 2025, then slumped by 40.63% to $31.8 million in 2026.
• The last three Common Equity figures came in at $31.8 million (Q1 2026), $53.5 million (Q4 2025), and $71.8 million (Q3 2025), per Business Quant data.